X4 Pharmaceuticals granted Fast Track designation for mavorixafor by FDA

X4 Pharmaceuticals (XFOR) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia. The company is currently conducting a global, pivotal Phase 3 clinical trial, 4WARD, evaluating mavorixafor in certain primary CN conditions. Mavorixafor was previously granted Fast Track designation for the treatment of WHIM syndrome, a rare immunodeficiency indication for which it received FDA approval in April 2024.